AN2 THERAPEUTICS, INC.

Analyst Reco. AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.27 ^USD	0.00%		-6.20%	-88.92%

May. 16	Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating	MT
Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating	May. 16	MT
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform	Apr. 02	MT
Leerink Partners Downgrades AN2 Therapeutics to Market Perform From Outperform, Adjusts PT to $7 From $23	Feb. 13	MT
Oppenheimer Downgrades AN2 Therapeutics to Market Perform From Outperform	Feb. 12	MT
Evercore ISI Downgrades AN2 Therapeutics to In Line from Outperform, Adjusts PT to $7 From $25	Feb. 12	MT
JMP Securities Downgrades AN2 Therapeutics to Market Perform From Market Outperform	Feb. 12	MT
JMP Securities Initiates AN2 Therapeutics With Market Outperform Rating, Price Target is $30	Jan. 04	MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $27 From $24, Maintains Outperform Rating	23-09-14	MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $24 From $20, Maintains Outperform Rating	23-03-30	MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $20 From $22, Maintains Outperform Rating	22-11-10	MT
Evercore ISI Initiates Coverage on AN2 Therapeutics With Outperform Rating, $25 Price Target	22-04-19	MT
Oppenheimer Initiates Coverage on AN2 Therapeutics With Outperform Rating, $22 Price Target	22-04-19	MT
Cowen Starts AN2 Therapeutics at Outperform	22-04-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW